As oncologic patients undergoing palliative care are reported to prefer oral treatment over intravenous application, repurposing well-established mTOR inhibitors and anti-endocrine agents for advanced cervical cancer could prove particularly beneficial [44]. This evidence concerns the gene MTOR and cervical carcinoma.